India’s Sun Pharma posts lower quarterly profit on one-time acquisition-related charge
Jenna Larson has been reporting on the Fargo region for over 15 years. She graduated from North Dakota State University and began her career at The Forum of Fargo-Moorhead before joining the Bison Current network. Jenna's focus is on community events, local initiatives, and the stories that make Fargo unique.
More from Jenna →
Oct 30 (Reuters) India s Sun Pharmaceutical Industries reported a drop in second-quarter profit on Friday, dragged by a one-time charge related to its acquisition of Organon. Consolidated net profit fell to 19.89 billion rupees ($209.31 million) in the quarter ended September 30 from 31.18 billion rupees a year earlier. The drugmaker booked a one-time charge of 12.69 billion rupees, largely comprising acquisition-related costs for its planned purchase of Organon, along with provisions linked to India s new labour code framework. ($1 = 95.0250 Indian rupees) (Reporting by Kashish Tandon in Bengaluru; Editing by Jochelle Mendonca)